[HTML][HTML] Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
Z Kong, C Yan, R Zhu, J Wang, Y Wang, Y Wang… - NeuroImage: Clinical, 2018 - Elsevier
Antiangiogenic therapy is a universal approach to the treatment of malignant gliomas but
fails to prolong the overall survival of newly diagnosed or recurrent glioblastoma patients …
fails to prolong the overall survival of newly diagnosed or recurrent glioblastoma patients …
A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: safety, efficacy, visual morbidity, and outcomes
K Green, P Panagopoulou, F D'Arco, P O'Hare… - Neuro …, 2023 - academic.oup.com
Background Bevacizumab is increasingly used in children with pediatric low-grade glioma
(PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to …
(PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to …
Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: a retrospective nationwide multicentre study
CAM Bennebroek, J van Zwol, GL Porro, R Oostenbrink… - Cancers, 2022 - mdpi.com
Simple Summary Around 30% of children with optic pathway glioma (OPG) require next
order systemic anticancer therapy (SAT) in case of progression. Bevacizumab (BVZ) is …
order systemic anticancer therapy (SAT) in case of progression. Bevacizumab (BVZ) is …
Use of antiangiogenic therapies in pediatric solid tumors
C Ollauri-Ibáñez, I Astigarraga - Cancers, 2021 - mdpi.com
Simple Summary Cancer is one of the leading causes of death in children worldwide. One of
the basic mechanisms for cancer development, both in children and in adults, is …
the basic mechanisms for cancer development, both in children and in adults, is …
Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates
Background Successful management of pediatric low-grade glioma (pLGG) can be
complicated by eloquent anatomical location, as well as specific pathologic and molecular …
complicated by eloquent anatomical location, as well as specific pathologic and molecular …
Fotemustine in recurrent high‑grade glioma: MRI neuro‑radiological findings
AP Savoldi, E Anghileri, M Moscatelli… - Oncology …, 2024 - spandidos-publications.com
The use of fotemustine (FTM) has been authorized in certain countries for the treatment of
recurrent high-grade gliomas (HGG) after Stupp therapy. However, to the best of our …
recurrent high-grade gliomas (HGG) after Stupp therapy. However, to the best of our …
Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta‐analysis and Systematic Review
Y Xu, Q Li, HY Ma, T Sun, RL Xiang… - Journal of clinical …, 2020 - Wiley Online Library
What is known and objective Bevacizumab (BVZ) is an angiogenesis inhibitor that often
works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in …
works well with chemotherapeutic drugs for the treatment of solid intracranial tumours in …
Safety of bevacizumab in patients younger than 4 years of age
NC Millan, MJ Poveda, O Cruz, J Mora - Clinical and Translational …, 2016 - Springer
Purpose Limited data exist regarding the safety and efficacy of bevacizumab in pediatric
patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 …
patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 …
[HTML][HTML] Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
M Simão-Rafael, O Cruz, S Perez-Jaume… - EJC Paediatric …, 2023 - Elsevier
Purpose Pediatric low-grade gliomas (PLGG) have an excellent overall survival, but
frequently need non-surgical therapy at diagnosis or after progression when located in …
frequently need non-surgical therapy at diagnosis or after progression when located in …
ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium
S Vajapeyam, D Brown, A Ziaei, S Wu… - American Journal …, 2022 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Selumetinib is a promising MAP (mitogen-activated
protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We …
protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We …